Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28102919 | 0.82 | ALDH1A1 (0.40) | CYP3A4TP53ALDH1A1TSHR | |
| SCHEMBL1713075 | 0.82 | TSHR (0.50) | CYP3A4TP53ALDH1A1TSHR | |
| SCHEMBL9495189 | 0.82 | ALDH1A1 (0.40) | CYP3A4TP53ALDH1A1TSHR | |
| SCHEMBL3784461 | 0.82 | TSHR (0.41) | CYP3A4TP53ALDH1A1TSHR | |
| SCHEMBL7182051 | 0.80 | CYP3A4 (0.60) | CYP3A4TP53ALDH1A1THRBTSHR | |
| SCHEMBL3792826 | 0.76 | CYP3A4 (0.48) | CYP3A4TP53ALDH1A1 | |
| SCHEMBL11527121 | 0.73 | ALDH1A1 (0.60) | ALDH1A1TSHR | |
| SCHEMBL9910728 | 0.73 | RAPGEF4 (0.34) | TSHR | |
| SCHEMBL16864347 | 0.73 | CYP3A4 (0.56) | CYP3A4TP53ALDH1A1TSHR | |
| SCHEMBL127074 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300465-B1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LTD (GB) | 2019-04-17 | — | — | EP | disclosed |
| US-8796244-B2 | Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases | ASTEX THERAPEUTICS LTD (GB) | 2014-08-05 | — | — | US | disclosed |
| US-20120208791-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2012-08-16 | — | — | US | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208791-A1 | IMIDAZOPYRIDINE DERIVATIVES AS INHIBITORS OF RECEPTOR TYROSINE KINASES | ABL1, ERBB2, RET | CYP3A4 1258/4885TP53 189/4885ALDH1A1 2527/4885 |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | CYP3A4 177/4885TP53 2819/4885ALDH1A1 4339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.